177 results match your criteria: "Juravinski Cancer Center[Affiliation]"
Eur Urol
October 2023
Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada. Electronic address:
Curr Oncol
April 2023
Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.
Background: Immune checkpoint inhibitors (ICI) are increasingly the mainstay of oncology treatment. Immune-related adverse events (irAEs) from ICI therapy differ from cytotoxic adverse events. Cutaneous irAEs are one of the most common irAEs and require careful attention to optimize the quality of life for oncology patients.
View Article and Find Full Text PDFGynecol Oncol
July 2023
Division of Gynecologic Oncology, Laval University, Quebec City, Canada. Electronic address:
Objective: Surgical margin status in women undergoing surgery for early-stage cervical cancer is an important prognostic factor. We sought to determine whether close (<3 mm) and positive surgical margins are associated with surgical approach and survival.
Methods: This is a national retrospective cohort study of cervical cancer patients treated with radical hysterectomy.
J Patient Rep Outcomes
April 2023
McMaster University, 1280 Main Street W, Hamilton, ON, L8S 4L8, Canada.
Purpose: The BREAST-Q is the most used patient-reported outcome measure (PROM) in breast cancer surgery. The purposes of this study were to re-examine the content validity of BREAST-Q cancer modules (mastectomy, lumpectomy and reconstruction) and to determine the need for new scales.
Methods: Interviews were conducted with women with breast cancer (Stage 0-4, any treatment), and were audio-recorded and transcribed verbatim.
Curr Oncol
February 2023
Juravinski Cancer Center, Hamilton Health Sciences, Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
Healthcare systems in Canada and elsewhere have identified the need to develop methods to effectively and safely transition appropriate cancer survivors to primary care. It is generally accepted that survivors with a low risk of adverse events, including recurrence and toxicity, should be more systematically identified and offered transition. There remains a lack of clarity about what constitutes an appropriate profile that would assist greater application in practice.
View Article and Find Full Text PDFJ Thorac Dis
February 2023
Radiation Oncology, Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada.
Background: Radiotherapy (RT) is used as monotherapy in poor performance patients with unresected locally advanced non-small cell lung cancer (LA-NSCLC), but their outcomes are not well-described. As novel therapies are increasingly considered in this space, it is important to understand contemporary outcomes of RT alone. Here, in this retrospective cohort study we analyzed LA-NSCLC outcomes of RT alone in Ontario, Canada, and contrasted them against those of standard of care (SoC) treatment of concurrent chemo-radiotherapy (cCRT).
View Article and Find Full Text PDFCurr Oncol
February 2023
Division of Gynecologic Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB T2N 4N2, Canada.
Minimally invasive surgery for the treatment of macroscopic cervical cancer leads to worse oncologic outcomes than with open surgery. Preoperative conization may mitigate the risk of surgical approach. Our objective was to describe the oncologic outcomes in cases of cervical cancer initially treated with conization, and subsequently found to have no residual cervical cancer after hysterectomy performed via open and minimally invasive approaches.
View Article and Find Full Text PDFJCO Oncol Pract
April 2023
Department of Medicine, University of Toronto, Toronto, ON, Canada.
Purpose: The role of frailty in affecting survival in myelodysplastic syndromes (MDS) is increasingly recognized. Despite this, a paucity of data exists on the association between frailty and other clinically meaningful outcomes including health care resource utilization and costs of care.
Methods: We linked the Ontario subset of the prospective Canadian MDS registry (including baseline patient/disease characteristics) to population-based health system administrative databases.
Int J Radiat Oncol Biol Phys
May 2023
Emory University Nell Hodgson Woodruff School of Nursing, Atlanta, Georgia.
Purpose: Rurality and neighborhood deprivation can contribute to poor patient-reported outcomes, which have not been systematically evaluated in patients with specific cancers in national trials. Our objective was to examine the effect of rurality and neighborhood socioeconomic and environmental deprivation on patient-reported outcomes and survival in men with prostate cancer in NRG Oncology RTOG 0415.
Methods And Materials: Data from men with prostate cancer in trial NRG Oncology RTOG 0415 were analyzed; 1,092 men were randomized to receive conventional radiation therapy or hypofractionated radiation therapy.
Clin Oncol (R Coll Radiol)
February 2023
Department of Radiation Oncology, Escarpment Cancer Research Institute, Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada. Electronic address:
Aims: To assess the risk of cardiac toxicity following radical radiotherapy in advanced lung cancer patients.
Materials And Methods: Patients with a diagnosis of stage III non-small cell lung cancer (NSCLC) receiving chemoradiotherapy were extracted from a population-based cohort in Ontario, Canada. The primary outcome of cardiac toxicity, defined as cardiac events or congestive heart failure, was assessed at 1 and 5 years following chemoradiotherapy.
Adv Radiat Oncol
September 2022
Medical Sciences Division, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
Purpose: Nontargeted low-dose ionizing radiation has been proposed as a cancer therapeutic for several decades; however, questions remain about the duration of hematological changes and optimal dosing regimen. Early studies delivering fractionated low doses of radiation to patients with cancer used varying doses and schedules, which make it difficult to standardize a successful dose and scheduling system for widespread use. The aim of this phase 2 two-stage trial was to determine whether low-dose radiation therapy (LD-RT) reduced prostate-specific antigen (PSA) in patients with recurrent prostate cancer in efforts to delay initiation of conventional therapies that are known to decrease quality of life.
View Article and Find Full Text PDFCarfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a real-world setting in Canada between years 2007 and 2020. A total of 445 patients were included in this study: the doublet (Kd/p, = 218) and triplets (KCd, = 88; KRd, = 99; KPd/p, = 40).
View Article and Find Full Text PDFRadiologia (Engl Ed)
November 2022
Departamento de Radiología, Juravinski Cancer Center y St. Josephs Healthcare, Hamilton, Universidad McMaster, Ontario, Canada; Departamento de Radiología, Universidad de Ottawa, Ontario, Canada.
Fungal lung co-infections associated with COVID-19 may occur in severely ill patients or those with underlying co-morbidities, and immunosuppression. The most common invasive fungal infections are caused by aspergillosis, mucormycosis, pneumocystis, cryptococcus, and candida. Radiologists integrate the clinical disease features with the CT pattern-based approach and play a crucial role in identifying these co-infections in COVID-19 to assist clinicians to make a confident diagnosis, initiate treatment and prevent complications.
View Article and Find Full Text PDFActa Neuropathol
December 2022
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Glioblastoma (GBM) is characterized by extensive cellular and genetic heterogeneity. Its initial presentation as primary disease (pGBM) has been subject to exhaustive molecular and cellular profiling. By contrast, our understanding of how GBM evolves to evade the selective pressure of therapy is starkly limited.
View Article and Find Full Text PDFGynecol Oncol
November 2022
Juravinski Cancer Center, Hamilton Health Sciences and McMaster University, Canada; Sheba Medical Center, Ramat Gan, Israel.
Objective: BRCA mutations have been associated with improved outcomes in ovarian cancer patients. This study's objective was to compare the secondary cytoreduction surgery (SCS) rates among ovarian cancer patients by BRCA mutation status.
Methods: The study was retrospective and included platinum sensitive recurrent high grade serous ovarian cancer patients from one Canadian center and two Israeli centers from January 1999 to December 2018.
Radiologia (Engl Ed)
August 2022
Departamento de Radiología, Universidad de Ottawa, Ottawa, Ontario, Canada.
Artificial Intelligence has the potential to disrupt the way clinical radiology is practiced globally. However, there are barriers that radiologists should be aware of prior to implementing Artificial Intelligence in daily practice. Barriers include regulatory compliance, ethical issues, data privacy, cybersecurity, AI training bias, and safe integration of AI into routine practice.
View Article and Find Full Text PDFJ Exp Clin Cancer Res
August 2022
SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Background: Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos exposure. There are few effective treatment options for mesothelioma, and patients have a very poor prognosis. Mesothelioma has the potential to represent an appropriate disease to prevent because of its strong association with asbestos exposure and the long latency from exposure to the disease on-set.
View Article and Find Full Text PDFJ Clin Oncol
January 2023
Providence-St. Paul's Hospital, Vancouver, BC, Canada.
Purpose: Organ-sparing therapy for early-stage I/IIA rectal cancer is intended to avoid functional disturbances or a permanent ostomy associated with total mesorectal excision (TME). The objective of this phase II trial was to determine the outcomes and organ-sparing rate of patients with early-stage rectal cancer treated with neoadjuvant chemotherapy followed by transanal excision surgery (TES).
Methods: This phase II trial included patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma eligible for endoscopic resection who were treated with 3 months of chemotherapy (modified folinic acid-fluorouracil-oxaliplatin 6 or capecitabine-oxaliplatin).
Ther Adv Med Oncol
July 2022
Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare system.
Methods: A cost-effectiveness analysis was conducted using a decision analytic Markov model from the Canadian public payer (Ontario) perspective and a 2-year time horizon in patients with treatment-naïve stage IV non-squamous NSCLC and ⩽10 pack-year smoking history.
Radiologia
July 2022
Departamento de Radiología, Juravinski Cancer Center y St. Josephs Healthcare, Hamilton, Universidad McMaster, Ontario, Canadá.
Fungal lung co-infections associated with COVID-19 may occur in severely ill patients or those with underlying co-morbidities, and immunosuppression. The most common invasive fungal infections are caused by aspergillosis, mucormycosis, pneumocystis, cryptococcus, and candida. Radiologists integrate the clinical disease features with the CT pattern-based approach and play a crucial role in identifying these co-infections in COVID-19 to assist clinicians to make a confident diagnosis, initiate treatment and prevent complications.
View Article and Find Full Text PDFJ Surg Oncol
November 2022
Sunnybrook Health Sciences Center, Toronto, Ontario, Canada.
Objective: To develop machine-learning models to predict recurrence and time-to-recurrence in high-grade endometrial cancer (HGEC) following surgery and tailored adjuvant treatment.
Methods: Data were retrospectively collected across eight Canadian centers including 1237 patients. Four models were trained to predict recurrence: random forests, boosted trees, and two neural networks.
Ther Adv Med Oncol
June 2022
Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30% of cases diagnosed at the advanced or metastatic stage. While single-agent vascular endothelial growth factor-targeted therapy has been a mainstay of treatment, data from multiple phase III trials assessing first-line immune checkpoint inhibitor (ICI) combinations have demonstrated a significant survival benefit.
Methods: A systematic search of the published and presented literature was performed to identify phase III trials assessing ICI combination regimens in RCC using search terms 'immune checkpoint inhibitors' AND 'renal cell carcinoma,' AND 'advanced'.
JCO Clin Cancer Inform
June 2022
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.
Purpose: To compare the predictive ability of mapping algorithms derived using cross-sectional and longitudinal data.
Methods: This methodological assessment used data from a randomized controlled noninferiority trial of patients with low-risk prostate cancer, conducted by NRG Oncology (ClinicalTrials.gov identifier: NCT00331773), which examined the efficacy of conventional schedule versus hypofractionated radiation therapy (three-dimensional conformal external beam radiation therapy/IMRT).
Clin Oncol (R Coll Radiol)
September 2022
Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. Electronic address:
Aim: To determine the efficacy of preoperative chemoradiotherapy as per the CROSS protocol for oesophageal/gastroesophageal junction cancer (OEGEJC), when expanded to patients outside of the inclusion/exclusion criteria defined in the original clinical trial.
Materials And Methods: Data were collected retrospectively on 229 OEGEJC patients referred for curative-intent preoperative chemoradiotherapy. Outcomes including pathological complete response (pCR), overall survival (OS), cancer-specific survival and recurrence-free survival (RFS) of patients who met CROSS inclusion criteria (MIC) versus those who failed to meet criteria (FMIC) were determined.
Objective: Although minimally invasive hysterectomy (MIS-H) has been associated with worse survival compared to abdominal hysterectomy (AH) for cervical cancer, only 8% of patients in the LACC trial had microinvasive disease (Stage IA1/IA2). We sought to determine differences in outcome among patients undergoing MIS-H, AH or combined vaginal-laparoscopic hysterectomy (CVLH) for microinvasive cervical cancer.
Methods: A retrospective cohort study of all patients undergoing hysterectomy (radical and non radical) for FIGO 2018, microinvasive cervical cancer across 10 Canadian centers between 2007 and 2019 was performed.